Cowen & Co. Initiates Coverage On Amedisys with Market Perform Rating, Announces Price Target of $195
Cowen & Co. analyst Gary Taylor initiates coverage on Amedisys (NASDAQ:AMED) with a Market Perform rating and announces Price Target of $195.
Analyst Ratings For Amedisys
Over the past 3 months, 6 analysts have published their opinion on Amedisys (NASDAQ:AMED) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET on Monday, 29 stocks hit new 52-week lows.
What 6 Analyst Ratings Have To Say About Amedisys
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings:
Last 30 Days
1 Month Ago
2 Months Ago
Return on Capital Employed Overview: Amedisys
After pulling data from Benzinga Pro it seems like during Q2, Amedisys (NASDAQ:AMED) earned $78.14 million, a 13.49% increase from the preceding quarter. Amedisys also posted a total of $564.17 million in sales, a 5.03% increase since Q1.
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 83 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday morning, 67 companies achieved new lows for the year.
Credit Suisse Maintains Outperform on Amedisys, Lowers Price Target to $250
Credit Suisse maintains Amedisys (NASDAQ:AMED) with a Outperform and lowers the price target from $330 to $250.